Depressive Disorder, Major

"Depressive Disorder, Major" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Marked depression appearing in the involution period and characterized by hallucinations, delusions, paranoia, and agitation.

Descriptor ID	D003865
MeSH Number(s)	F03.600.300.375
Concept/Terms	Depressive Disorder, Major Depressive Disorder, Major Depressive Disorders, Major Disorder, Major Depressive Disorders, Major Depressive Major Depressive Disorders Major Depressive Disorder Psychosis, Involutional Psychosis, Involutional Involutional Psychoses Involutional Psychosis Psychoses, Involutional Paraphrenia, Involutional Paraphrenia, Involutional Involutional Paraphrenia Involutional Paraphrenias Paraphrenias, Involutional Depression, Involutional Depression, Involutional Involutional Depression Melancholia, Involutional Involutional Melancholia

Below are MeSH descriptors whose meaning is more general than "Depressive Disorder, Major".

Psychiatry and Psychology [F]
Mental Disorders [F03]
Mood Disorders [F03.600]
Depressive Disorder [F03.600.300]
Depressive Disorder, Major [F03.600.300.375]

Below are MeSH descriptors whose meaning is related to "Depressive Disorder, Major".

Below are MeSH descriptors whose meaning is more specific than "Depressive Disorder, Major".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Depressive Disorder, Major" by people in this website by year, and whether "Depressive Disorder, Major" was a major or minor topic of these publications.

Bar chart showing 217 publications over 26 distinct years, with a maximum of 17 publications in 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	1	1	2
2001	0	1	1
2002	2	1	3
2003	4	0	4
2004	6	1	7
2005	4	0	4
2006	5	1	6
2007	10	2	12
2008	9	2	11
2009	7	1	8
2010	10	2	12
2011	12	2	14
2012	5	4	9
2013	11	2	13
2014	8	1	9
2015	10	0	10
2016	7	0	7
2017	7	2	9
2018	6	2	8
2019	13	1	14
2020	8	1	9
2021	16	1	17
2022	7	0	7
2023	11	0	11
2024	6	1	7
2025	3	0	3

Below are the most recent publications written about "Depressive Disorder, Major" by people in Profiles.

Butterfield NN, Luzon Rosenblut C, Fava M, Correll CU, Rothschild AJ, Murrough JW, Mathew SJ, Beatch GN, Grayson C, Harden C, Qian J, McIntosh J, Namdari R, Kenney C. Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major Depressive Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2025 May 01; 8(5):e2514278.

View in: PubMed
Miller BR, Gonzaga-Jauregui C, Brigatti KW, de Jong J, Breese RS, Ko SY, Puffenberger EG, Van Hout C, Young M, Luna VM, Staples J, First MB, Gregoire HJ, Dwork AJ, Pefanis E, McCarthy S, Brydges S, Rojas J, Ye B, Stahl E, Di Gioia SA, Hen R, Elwood K, Rosoklija G, Li D, Mellis S, Carey D, Croll SD, Overton JD, Macdonald LE, Economides AN, Shuldiner AR, Chuhma N, Rayport S, Amin N, Kushner SA, Alessandri-Haber N, Markx S, Strauss KA. A rare variant in GPR156 associated with depression in a Mennonite pedigree causes habenula hyperactivity and stress sensitivity in mice. Proc Natl Acad Sci U S A. 2025 Apr 22; 122(16):e2404754122.

View in: PubMed
Carter E, Banerjee S, Alexopoulos GS, Bingham KS, Marino P, Meyers BS, Mulsant BH, Neufeld NH, Rothschild AJ, Voineskos AN, Whyte EM, Flint AJ. Prediction of remission of pharmacologically treated psychotic depression: A machine learning approach. J Affect Disord. 2025 Jul 15; 381:291-297.

View in: PubMed
Franklin CE, Achtyes E, Altinay M, Bailey K, Bhati MT, Carr BR, Conroy SK, Husain MM, Khurshid KA, Lencz T, McDonald WM, Mickey BJ, Murrough J, Nestor S, Nickl-Jockschat T, Nikayin S, Reeves K, Reti IM, Selek S, Sanacora G, Trapp NT, Viswanath B, Wright JH, Sullivan P, Zandi PP, Potash JB. The genetics of severe depression. Mol Psychiatry. 2025 Mar; 30(3):1117-1126.

View in: PubMed
Bareis N, Edlund M, Ringeisen H, Guyer H, Dixon LB, Olfson M, Smith TE, Chwastiak L, Monroe-DeVita M, Swartz M, Swanson J, Sinclair Hancq E, Geiger P, Kreski NT, Stroup TS. Characterizing Schizophrenia Spectrum Disorders: Results of the U.S. Mental and Substance Use Disorders Prevalence Study. Psychiatr Serv. 2025 Jan 01; 76(1):2-12.

View in: PubMed
Rothschild AJ. Question: How Should I Switch From One Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin and Norepinephrine Reuptake Inhibitor (SNRI) to Another SSRI or SNRI in a Patient With Major Depressive Disorder? J Clin Psychopharmacol. 2024 Sep-Oct 01; 44(5):531-532.

View in: PubMed
Jasuja GK, Reisman JI, Miller DR, Ansara ED, Chiulli DL, Moore T, Ourth HL, Tran MH, Smith EG, Morreale AP, McCullough MM. Complexity of patients with mental healthcare needs cared for by mental health clinical pharmacist practitioners in Veterans Affairs. Am J Health Syst Pharm. 2024 May 24; 81(11):e289-e295.

View in: PubMed
Kim HK, Voineskos AN, Neufeld NH, Alexopoulos GS, Bingham KS, Flint AJ, Marino P, Rothschild AJ, Whyte EM, Mulsant BH. Effect of olanzapine exposure on relapse and brain structure in patients with major depressive disorder with psychotic features. Mol Psychiatry. 2024 Aug; 29(8):2459-2466.

View in: PubMed
Clayton AH, Suthoff E, Jain R, Kosinski M, Fridman M, Deligiannidis KM, Meltzer-Brody S, Chen SY, Gervitz L, Huang MY, Trivedi M, Bonthapally V. The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials. J Affect Disord. 2024 04 15; 351:904-914.

View in: PubMed
Rothschild AJ. Maintenance treatment of psychotic depression: Is antipsychotic medication needed? Acta Psychiatr Scand. 2024 01; 149(1):3-5.

View in: PubMed

People

Explore

Similar Concepts

Top Journals